Focused On-demand Library for Probable palmitoyltransferase ZDHHC11B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P0C7U3

UPID:

ZH11B_HUMAN

Alternative names:

Zinc finger DHHC domain-containing protein 11B

Alternative UPACC:

P0C7U3; A6NHR3

Background:

Probable palmitoyltransferase ZDHHC11B, also known as Zinc finger DHHC domain-containing protein 11B, plays a crucial role in cellular processes through its probable function in catalyzing the addition of palmitate onto various protein substrates. This enzymatic activity is pivotal for the modification of proteins, influencing their localization, stability, and interaction with other cellular components.

Therapeutic significance:

Understanding the role of Probable palmitoyltransferase ZDHHC11B could open doors to potential therapeutic strategies. Its involvement in cell proliferation, as indicated by scientific studies, highlights its significance in cellular growth and division, making it a potential target for therapeutic intervention in diseases characterized by abnormal cell proliferation.